Home›Trial›NCT05456685
🔬NCT05456685Phase 2ACTIVE NOT RECRUITING

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Study Summary

IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy.

Conditions
High Grade Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Interventions / Drugs
Mirvetuximab soravtansineCarboplatin
View on ClinicalTrials.gov ↗
Sponsor
ABBV
AbbVie Inc
Immunology
C64/100
Study Details
Enrollment125 participants
Primary Completion—
Lead SponsorAbbVie
Data Retrieved2026-04-11 02:51:51.324778+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.